Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: Implications for dosing

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 6, 2014, Pages 1804-1811

  Jitmuang, Anupop ^a   Nation, Roger L ^b   Koomanachai, Pornpan ^a   Chen, Gong ^b   Lee, Hee Ji ^b   Wasuwattakul, Somkiat ^a   Sritippayawan, Suchai ^a   Li, Jian ^b   Thamlikitkul, Visanu ^a   Landersdorfer, Cornelia B ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Determination of extracorporeal clearance by multiple methods; Polymyxins; Population pharmacokinetics; Renal replacement therapy

Indexed keywords

COLISTIMETHATE; COLISTIN; ANTIINFECTIVE AGENT; COLISTINMETHANESULFONIC ACID; PRODRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DIALYSATE; DRUG ADSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; END STAGE RENAL DISEASE; EXTRACORPOREAL CLEARANCE; FEMALE; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; URINALYSIS; ANALOGS AND DERIVATIVES; BLOOD ANALYSIS; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE, CHRONIC; METABOLIC CLEARANCE RATE; MIDDLE AGED; RENAL REPLACEMENT THERAPY; STATISTICAL MODEL; TIME;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTI-BACTERIAL AGENTS; BLOOD CHEMICAL ANALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLISTIN; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, STATISTICAL; PRODRUGS; RENAL DIALYSIS; TIME FACTORS; URINALYSIS;

EID: 84930520421     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv031     Document Type: Article

References (25)

1. Calfee DP. Multidrug-resistant organisms in dialysis patients. Semin Dial 2013; 26: 447-56.
2. Gobin P, Lemaitre F, Marchand S et al. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother 2010; 54: 1941-8.
3. Paksu MS, Paksu S, Karadag A et al. Old agent, new experience: colistin use in the paediatric Intensive Care Unit-a multicentre study. Int J Antimicrob Agents 2012; 40: 140-4.
4. Markou N, Apostolakos H, Koumoudiou C et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003; 7: R78-83.
5. Bassetti M, Repetto E, Righi E et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008; 61: 417-20.
6. Reina R, Estenssoro E, Saenz G et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 2005; 31: 1058-65.
7. Koomanachai P, Tiengrim S, Kiratisin P et al. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis 2007; 11: 402-6.
8. Li J, Nation RL, Turnidge JD et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601.
9. Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis 2009; 22: 535-43.
10. Garonzik SM, Li J, Thamlikitkul V et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55: 3284-94.
11. Marchand S, Frat JP, Petitpas F et al. Removal of colistin during intermittent haemodialysis in two critically ill patients. J Antimicrob Chemother 2010; 65: 1836-7.
12. Luque S, Sorli L, Li J et al. Effective removal of colistin methanesulphonate and formed colistin during intermittent haemodialysis in a patient infected by polymyxin-only-susceptible Pseudomonas aeruginosa. J Chemother 2014; 26: 122-4.
13. EMA. Product information of CMS-containing products for injection or infusion. Annex III: Amendments to relevant sections of the summary of product characteristics and the package leaflets. Approved by the CHMPon 23 October 2014, pending endorsement by the European Commission.
14. Dudhani RV, Nation RL, Li J. Evaluating the stability of colistin and colistin methanesulphonate in human plasma under different conditions of storage. J Antimicrob Chemother 2010; 65: 1412-5.
15. Li J, Milne RW, Nation RL et al. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother 2002; 46: 3304-7.
16. Li J, Milne RW, Nation RL et al. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001; 761: 167-75.
17. Gabrielsson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. Stockholm, Sweden: CRC Press, 2001.
18. Bauer RJ. S-ADAPT/MCPEM User's Guide (Version 1.57). Software for Pharmacokinetic, Pharmacodynamic and Population Data Analysis. Berkeley, CA: Biomedical Simulations Resource (BMSR) at the University of Southern California (USC), 2010.
19. Bulitta JB, Landersdorfer CB. Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models. AAPS J 2011; 13: 212-26.
20. Bulitta JB, Bingolbali A, Shin BS et al. Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. AAPS J 2011; 13: 201-11.
21. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481-504.
22. Koomanachai P, Landersdorfer CB, Chen G et al. Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 2014; 58: 440-6.
23. Mohamed AF, Karaiskos I, Plachouras D et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 2012; 56: 4241-9.
24. Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gramnegative bacteria. Antimicrob Agents Chemother 2009; 53: 3430-6.
25. Li J, Milne RW, Nation RL et al. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004; 53: 837-40.